Mutational spectrum of Gelsolin and its down regulation is associated with breast cancer

Disease Markers

Volumn 34, Issue 2, 2013, Pages 71-80

  Baig, Ruqia Mehmood ^a   Mahjabeen, Ishrat ^a   Sabir, Maimoona ^a   Masood, Nosheen ^a   Ali, Kashif ^a   Malik, Faraz Arshad ^a,b   Kayani, Mahmood Akhtar ^a  

^a COMSATS Institute of Information Technology ^*  (Pakistan)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

breast cancer; expressional analysis; Gelsolin; germline mutations; PCR SSCP; quantitative real time PCR

Indexed keywords

GELSOLIN; GLUTAMINE; GLYCINE; LEUCINE; LYSINE; PHENYLALANINE;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EXON; FEMALE; FOLLOW UP; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC VARIABILITY; GERM LINE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PAKISTAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 84873663097     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/795410     Document Type: Article

References (62)

1. A. D. Thor, S. M. Edgerton, S. Liu, D. H. Moore and D. J. Kwiatkowski, Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers, Clin Cancer Res 7 (2001), 2415-24.
2. A. J. Sanders, C. Parr, M. D. Mason andW. G. Jiang, Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro, Int J Mol Med 20 (2007), 613-19.
3. A. Noske, C. Denkert, H. Schober, C. Sers, B. Zhumabayeva, W. Weichert, M. Dietel and K. Wiechen, Loss of Gelsolin expression in human ovarian carcinomas, Eur J Cancer 41 (2005), 461-9.
4. A.V. Abbeele, V. D. Corte, K. Van Impe, E. Bruyneel, C. Boucherie, M. Bracke, J. Vandekerckhove and J. Gettemans, Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro, Cancer Letters 255 (2007), 57-70.
5. C. C. Thompson, F. J. Ashcroft, S. Patel, G. Saraga, D. Vimalachandran, W. Prime, F. Campbell, A. Dodson, R. E. Jenkins, N. R. Lemoine, T. Crnogorac-Jurcevic, H. L. Yin and E. Costello, Pancreatic cancer cells over express gelsolin family capping proteins which contribute to their cell motility, Gut 56 (2007), 95-106.
6. C. Chaponnier and G. Gabbiani, Gelsolin modulation in epithelial and stromal cells ofmammary carcinoma, Am. JPathol 134 (1989), 597-603.
7. C. Chaponnier, A. J. Paul and H. L. Yin, The Actin Filamentsevering Domain of Plasma Gelsolin, The Journal of Cell Biology 103 (1986), 1473-81.
8. C. G. dos Remedios, D. Chhabra, M. Kekic, I. V. Dedova, M. Tsubakihara, D. A. Berry and N. J. Nosworthy, Actin binding proteins: Regulation of cytoskeletal microfilaments. Physiol 83 (2003), 433-73.
9. D. J. Kwiatkowski, Functions of gelsolin: Motility, signaling, apoptosis, cancer. Curr Opin Cell Bio 11 (1999), 103-8.
10. D. Yamazaki, S. Kurisu and T. Takenawa, Regulation of cancer cell motility through actin reorganization, Cancer Sci 96 (2005), 379-86.
11. D. B. Shieh, I. W. Chen, T. Y. Wei, C. Y. Shao, H. J. Chang, C. H. Chung, T. Y. Wong and Y. T. Jin, Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications, Oral Oncol 42 (2006), 599-606.
12. E. Irobi, L. D. Burtnick, D. Urosev, K. Narayan and R. C. Robinson, From the first to the second domain of gelsolin: A common path on the surface of actin? FEBS Lett 552 (2003), 86-90.
13. F. Yu, H. Sun, P. Janmey and H. Yin, Identification of a Polyphosphoinositide-binding sequence in an actin monomerbinding domain of gelsolin, Jour Biol Chem 267 (1992), 14616-21.
14. H. Choe, L. D. Burtnick, M.Mejillano, H. L. Yin, R.C. Robinson and S. Choe, The calcium activation of gelsolin: Insights from the 3A structure of the G4-G6/actin complex, J Mol Biol 324 (2002), 691-702.
15. H. Dosaka-Akita, F. Hommura, H. Fujita, I. Kinoshita, M. Nishi, T. Morikawa, H. Katoh, Y. Kawakami and N. Kuzumaki, Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers, Cancer Res 58 (1998), 322-7.
16. H. Fujita, F. Okada, J-I Hamada,MHosokawa, TMoriuchi, R. C. Koya and N. Kuzumaki, Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect, Int J Cancer 93 (2001), 773-780.
17. H. Fujita, L. E. Laham, P. A. Janmey, D. J. Kwiatkowski, T. p. Stossel, Y. Banno, Y. Nozawa, L.M?ullauer, A. Ishizaki and N. Kuzumaki, Functions of [His321] gelsolin isolated from a flat revertant of ras-transformed cells, Eur J Biochem 229 (1995), 615-20.
18. H. K. Lee, D. Driscoll, H. Asch, B.Asch and P. J. Zhang, Down regulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate, Prostate 40 (1999), 14-19.
19. H. L. Asch, J. S.Winston, S. B. Edge, P. C. Stomper and B. B. Asch, Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion, Breast Cancer Res Treat 55 (1999), 179-88.
20. H. L. Asch, K. Head, Y. Dong, F. Natoli, J. S. Winston, J. L. Connolly and B. B.Asch,Widespread loss of gelsolin in breast cancers of humans, mice, and rats, Cancer Res 56 (1996), 4841-45.
21. H. Q. Sun, M. Yamamoto, M. Mejillano and H. L. Yin, Gelsolin, a multifunctional actin regulatory protein, J Biol Chem 274 (1999), 33179-82.
22. H. Su, T. Wang, H. Dong and H. Ren, The Villin/Gelsolin/Fragmin Superfamily proteins in plants, JIPB 49 (2007), 1183-1191.
23. H. Tanaka, R. Shirkoohi, K. Nakagawa, H. Qiao, H. Fujita, F. Okada, J. I. Hamada, S.Kuzumaki, M. Takimoto andN. Kuzumaki, siRNA gelsolin knockdown induces epithelial - mesenchymal transition with a cadherin switch in human mammary epithelial cells, Int J Cancer 118 (2005), 1680-91.
24. I. Mahjabeen, R. M. Baig, N. Masood, M. Sabir, F. A. Malik and M. A. Kayani, Sequence Variation of the OGG1 Gene in Head and Neck Cancer Patients in Pakistan, Asian Pacific J Cancer Prev 12 (2011), 2359-63.
25. J. Gettemans, A. V. Abbeele, A.De Ganck, K. Meerschaert, J. Vandekerckhobe and V. de Corte, Gelsolin and Tumor Metastasis: Friend or Foe? in: New development in metastasis suppressor research, New York, Nova Science Publishers, 2007, pp. 103-121.
26. J. E. Cho, W. il Park, D. C. Kim, H. J. Kim, S. W. Kim, J. M. Kang and J. H. Cho, Down-regulation of gelsolin may play a role in the progression of inverted papilloma through an antiapoptotic mechanism, Am J Rhinol Allergy 26 (2012), 177-82.
27. J. G. Kiselar, P. A. Janmey, S. C. Almo and M. R. Chance, Structural analysis of gelsolin using synchrotron protein foot printing, Mol Cell Proteomics 2 (2003), 1120-32.
28. J. H. Hartwig and D. J. Kwiatkowski, Actin binding proteins, Curr Opin Cell Biol 3 (1991), 87-97.
29. J. H. Kim, Y. K. Choi, H. J. Kwon, H. K. Yang, J. H. Choi and D. Y. Kim, Down regulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase, J Gastroenterol Hepatol 19 (2004), 218-24.
30. J. Rao, D. Seligson, H. Visapaa, S. Horvath, M. Eeva, K. Michel, A. Pantuck, A. Belldegrun and A. Palotie, Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma, Cancer 95 (2002), 1247-57.
31. J. S.Winston, H. L. Asch, P. J. Zhang, S. B. Edge,A.H.Hyland and B. B. Asch, Down-regulation of gelsolin correlates with the progression to breast cancer, Breast Cancer Res Treat 65 (2001), 11-2.
32. J. S.Winston, H. L. Asch, P. J. Zhang, S. B. Edge,A.H.Hyland and B. B. Asch, Down-regulation of gelsolin correlates with the progression to breast cancer, Breast Cancer Res Treat 65 (2001), 11-2.
33. J. Vandekerckhove, Actin binding proteins, Curr Opin Cell Biol 2 (1990), 41-50.
34. J. Vanderkeckhove, G. Gauw, K. Vancompenolle, B. Honore and J. Celis, Comparative two-dimensional gel analysis and micro sequencing identifies gelsolin as one of the most prominent down-regulated markers of transformed human fibroblast and epithelial cells, J Cell Biol 111 (1990), 95-102.
35. J. Yang, D. Tan, H. L. Asch, H. Swede, G. Bepler, J. Geradts and K. B. Moysich, Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer, Lung Cancer 46 (2004), 29-42.
36. J. Yang, N. Ramnath, K. B. Moysich, H. L. Asch, H. Swede, S. J. Alrawi, J. Huberman, J. Geradts, J. S. Brooks and D. Tan, Prognostic significance of MCM2, Ki-67 and gelsolin in non small cell lung cancer, BMC Cancer 6 (2006), 203-13.
37. K. Haga, H. Fujita, M. Nomoto, A. Sazawa, K. Nakagawa, T. Harabayashi, N. Shinohara, M. Takimoto, K. Nonomura and N. Kuzumaki, Gelsolin gene silencing involving unusual hypersensitivities to dimethylsulfate and KMnO4 in vivo foot printing on its promoter region, Int J Cancer 111 (2004), 873-80.
38. K. Narayan, S. Chumnarnsilpa, H. Choe, E. Irobi, D. Urosev, U. Lindberg, C. E. Schutt, L. D. Burtnick and R. C. Robinson, Activation in isolation: exposure of the actin-binding site in the C-terminal half of gelsolin does not require actin, FEBS Lett 552 (2003), 82-85.
39. K. Uchida, N. Masumori, A. Takahashi, N. Itoh, K. Kato, R. J. Matusik and T. Tsukamoto, Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP, Prostate 66 (2006), 536-45.
40. L. A. Harold, H. Karen, D. Yan, N. Farah, J. C. Winston, L. C. James and B. A. Bonnie, Widespread Loss of Gelsolin in Breast Cancers of Humans, Mice, and Rats, CANCER RES 56 (1996), 4841-45.
41. L. D. Burtnick, E.K.Koepf, J.Grimes, E.Y. Jones, D. I. Stuart, P. J. McLaughlin and R. C. Robinson. The Crystal Structure of Plasma Gelsolin: Implications for Actin Severing, Capping, and Nucleation, Cell 90 (1997), 661-70.
42. L. Mullauer, H. Fujita, A. Ishizaki and N. Kuzumaki, Tumorsuppressive function of mutated gelsolin in ras-transformed cells, Oncogene 8 (1993), 2531-6.
43. L. Mullauer, H. Fujita, H. Suzuki, M. Katabami, Y. Hitomi, Y. Ogiso and N, Kuzumaki, Elevated gelsolin and α-actin expression in a flat revenant RI of Ha-ras oncogene-transformed NIH/3T3 cells, Biochem Biophys Res Commun 7 (1990), 852-59.
44. M. Tanaka, A. Sazawa, N. Shinohara, Y. Kobayashi, Y. Fujioka, T. Koyanagi and N. Kuzumaki, Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice, Cancer Gene Ther 6 (1999), 482-7.
45. M. Tanaka, L. Miillauer, Y. Ogiso, H. Fujita, S. Moriya, K. Furuuchi, T. Harabayashi, N. Shinohara, T. Koyanagi and N. Kuzumaki, Gelsolin: A Candidate for Suppressor of Human Bladder Cancer, Cancer Research 11 (1995), 3228-32.
46. M. U. Rashid, A. Zaidi, D. Torres, F. Sultan, A. Benner, B. Naqvi, A. R. Shakoori, A. Seidel-Renkert, H. Farooq, S. Narod, A. Amin and U. Hamann, Prevalence of BRCA1 and BRCA2mutations in Pakistani breast and ovarian cancer patients, Int J Cancer 119 (2006), 2832-39.
47. N. Sagawa, H. Fujita, Y. Banno, Y. Nozawa, H. Katoh and N. Kuzumaki, Gelsolin suppresses tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PPC10, Brit Jour of Canc 88 (2003), 606-12.
48. P. A. Janmey and T. P. Stossel, Modulation of gelsolin function by phosphatidylinositol 4, 5-bisphosphate, Nature (Lond) 325 (1987), 362-4.
49. P. C. Ng and S. Henikoff, SIFT: predicting amino acid changes that affect protein function, Nucleic Acids Res 31 (2003), 3812-14.
50. P. J. McLaughlin, J. T. Gooch, H. G. Mannherz and A. G. Weeds, Structure of gelsolin segment 1-actin complex and the mechanism of filament severing, Nature 364 (1993), 685-92.
51. P. Silacci, L. Mazzolai, C. Gauci, N. Stergiopulos, H. L. Yin and D. Hayoz, Gelsolin super family proteins: Key regulators of cellular functions, Cell Mol Life Sci 61 (2004), 2614-23.
52. R. M. Baig, I. Mahjabeen, M. Sabir, N. Masood, S. Hafeez, F. A. Malik and M. A. Kayani, Genetic Changes in PTEN Gene and their Association with Breast Cancer in Pakistan, Asian Pacific J Cancer Prev 12 (2011), 2365-70.
53. R. M. Porter, T. C. Holme, E. L. Newman, D. Hopwood, J. M. Wilkinson and A. Cuschieri, Monoclonal antibodies to cytoskeletal proteins: An immunohistochemical investigation of human colon cancer, J Pathol 170 (1993), 435-40.
54. S. A. Gangat, A. Rehman, M. A. Ahmed and I. A. Memon, Pattern of aetiological and predisposing factors regarding carcinoma breast, Pak J surg 23 (2007), 7-13.
55. S. Jin, J. Shen, J. Peng, J. Wang, G. Huang and M. Li, Decreased expression of serum gelsolin in patients with osteosarcoma, Chinese Medical Journal 125 (2012), 262-69.
56. S. Kothakota, T. Azuma, C. Reinhard, A. Klippel, J. Tang, K. Chu, T. J. McGarry, M. W. Kirschner, K. Koths, D. J. Kwiatkowski and L. T. Williams, Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis. Science 278 (1997), 294-8.
57. S. Langbein, J. Lehmann, A. Harder, A. Steidler, M. S. Michel, P. Alken and J. K. Badawi. Protein profiling of bladder cancer using the 2D-PAGE and SELDI-TOF-MS technique, Technol Cancer Res Treat 5 (2006), 67-72.
58. S. Moriya, K. Yanagihara, H. Fujita and N. Kuzumaki, Differential expression of HSP90, gelsolin and GST-Tr in human gastric carcinoma cell lines, Int J Oncol 5 (1994), 1347-51.
59. S. Sohail and S. N. I. Alam, Breast cancer in Pakistan - awareness and early detection, J Coll Physicians Surg Pak 17 (2007), 711-2.
60. D. Shieh, J. Godleski, J. E. Herndon, T. Azuma, H. Mercer, D. J. Sugarbaker and D. J. Kwiatkowski, Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: The role of gelsolin expression, Cancer 85 (1999), 47-57.
61. W.Witke, A. H. Sharpe, J.H. Hartwig, T.Azuma, T. P. Stossel, D. J. Kwiatkowski, Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin, Cell 81 (1995), 41-51.
62. Y. Banno, T. Nakashima, T. Kumada, K. Ebisawa, Y. Nonomura and Y. Nozawa, Effects of gelsolin on human platelet cytosolic phosphoinositide-phospholipase C. isozymes, J Biol Chem 267 (1992), 6488-94.